Exact Sciences
EXAS
$68.22
Share price
-1.36%
Change (1 day)
43.35%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Exact Sciences (EXAS) - Net assets
Net assets on the balance sheet as of June 2023 : $3.05 B
According to Exact Sciences's latest financial reports the company has $3.05 B in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Exact Sciences - Net assets on balance sheet (from 2001 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $3.04 B | -10.17% |
| 2021-12-31 | $3.38 B | 19.98% |
| 2020-12-31 | $2.82 B | 23.4% |
| 2019-12-31 | $2.28 B | 236.01% |
| 2018-12-31 | $0.68 B | 30.85% |
| 2017-12-31 | $0.52 B | 55.21% |
| 2016-12-31 | $0.33 B | 2.58% |
| 2015-12-31 | $0.32 B | 13.11% |
| 2014-12-31 | $0.28 B | 113.56% |
| 2013-12-31 | $0.13 B | 37.24% |
| 2012-12-31 | $98.59 M | 18.08% |
| 2011-12-31 | $83.49 M | 4.69% |
| 2010-12-31 | $79.75 M | 1200.41% |
| 2009-12-31 | $6.13 M | -352.08% |
| 2008-12-31 | $-2.44 M | -138.69% |
| 2007-12-31 | $6.28 M | -57.96% |
| 2006-12-31 | $14.95 M | -39.25% |
| 2005-12-31 | $24.62 M | -35.18% |
| 2004-12-31 | $37.98 M | 210.62% |
| 2003-12-31 | $12.22 M | -68.11% |
| 2002-12-31 | $38.34 M | -34.97% |
| 2001-12-31 | $58.96 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $79.27 B | 2,493.68% | 🇫🇷 France |
 Veracyte VCYT | $1.08 B | -64.58% | 🇺🇸 USA |
 Myriad Genetics MYGN | $0.73 B | -75.95% | 🇺🇸 USA |
 Biocept
BIOC | $0.29 M | -99.99% | 🇺🇸 USA |